CD44 and gastric cancer: A recent study of ten gastric cancer cell lines using PacBio’s Iso-Seq technology identified approximately 39,000 novel isoforms, including for the known oncogenes ERBB2 and CD44. Alternative promoters were frequently used in gastric cancer cells which often resulted in altered downstream CDS and 3′ UTRs (Huang et al., 2021).